Anaplastic large cell lymphoma (ALCL) is a heterogeneous subtype of T‐cell lymphoma predominantly driven by genetic alterations affecting the anaplastic lymphoma kinase (ALK) gene.[1] The current standard treatments involve chemotherapy alone or in combination with brentuximab vedotin (BV), achieving a cure rate of approximately 70% in patients with ALK‐positive (ALK+) ALCL.[2] Despite the relatively favorable prognosis of ALK+ ALCL, up to 30–40% of patients experience relapses or disease progression. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.